Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting approximately 6-10 million people globally[1]. The disease results from the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to characteristic motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability[2]. Non-motor symptoms such as sleep disorders, autonomic dysfunction, cognitive impairment, and psychiatric manifestations are also common and significantly impact quality of life[3].
Modern PD treatment encompasses symptomatic management, complication prevention, and emerging disease-modifying therapies. This guide provides an overview of the comprehensive treatment landscape.
Levodopa remains the gold standard for PD treatment[4]. As the dopamine precursor, it effectively controls motor symptoms but long-term use leads to motor complications.
Key formulations:
Dosing: Start at 25/100 mg three times daily, titrate to 300-1000 mg/day[6].
Dopamine agonists provide symptomatic relief by directly stimulating dopamine receptors[7].
Oral options:
Side effects: Nausea, somnolence, impulse control disorders, hallucinations.
MAO-B inhibitors extend dopamine availability by blocking its enzymatic breakdown[10].
COMT inhibitors prolong levodopa effect by blocking peripheral metabolism[13].
Provides modest benefit and uniquely reduces levodopa-induced dyskinesias.
Deep brain stimulation (DBS) is highly effective for advanced PD[15].
Targets: Subthalamic nucleus (STN) or Globus pallidus interna (GPi)[16]
Outcomes[17]:
Eligibility: ≥4 years disease duration, motor complications, no significant cognitive/psychiatric impairment[18]
| Agent | Target | Phase |
|---|---|---|
| Prasinezumab | α-synuclein | Phase 2 |
| BIIB122 (DNL151) | LRRK2 | Phase 2b |
| ACI-7104 | α-synuclein vaccine | Phase 1 |
| Venglustat | GCase | Phase 2 |
For detailed information on treatment protocols, see the full Parkinson's Disease Treatment page.
PD treatment has advanced significantly with multiple therapeutic options. Levodopa remains foundational, complemented by dopamine agonists, MAO-B inhibitors, and surgical interventions. Disease-modifying therapies targeting α-synuclein and LRRK2 offer future promise.
Pablo-Fernandez GD, et al. Global, regional, and national burden of Parkinson's disease, 1990-2021. Lancet Neurology. 2024. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008. ↩︎
Fahn S. How do you treat motor complications in Parkinson's disease?. J Neurol. 2005. ↩︎
Brooks DJ, et al. Enteral levodopa/carbidopa gel infusion for Parkinson's disease. Expert Opin Pharmacother. 2014. ↩︎
Poewe WH, et al. Diagnosis and management of Parkinson's disease in adults. Pract Neurol. 2020. ↩︎
Schapira AHV, et al. Therapeutic advances in Parkinson's disease. Mov Disord. 2019. ↩︎
Hubble JP, et al. Pramipexole in Parkinson's disease. Neurology. 2000. ↩︎
Adler CH, et al. Ropinirole for Parkinson's disease. Mov Disord. 2004. ↩︎
Riederer P, Laux G. MAO-B inhibitors for Parkinson's disease. J Neural Transm. 2011. ↩︎
Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009. ↩︎
Schapira AH, et al. Safinamide in Parkinson's disease. J Neural Transm. 2017. ↩︎
Antonini A, et al. Continuous dopaminergic stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders. 2016. ↩︎
Ferreira JJ, et al. Opicapone for Parkinson's disease. Expert Opin Pharmacother. 2016. ↩︎
Krack P, et al. Long-term follow-up of deep brain stimulation for Parkinson's disease. N Engl J Med. 2003. ↩︎
Volkmann J, et al. Deep brain stimulation for Parkinson's disease. Parkinsonism Relat Disord. 2010. ↩︎
Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease. Neurology. 2009. ↩︎
Bronstein JM, et al. Deep brain stimulation for Parkinson's disease. Neurology. 2011. ↩︎
Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020. ↩︎
Wang Y, et al. Acupuncture for Parkinson's disease: A systematic review and meta-analysis. Journal of Alternative and Complementary Medicine. 2020. ↩︎